HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees

Vaccine

Volumn 12, Issue 12, 1994, Pages 1141-1148

  Bruck, Claudine ^a   Thiriart, Clotilde ^a   Fabry, Luc ^a   Francotte, Myriam ^a   Pala, Pietro ^a   Van Opstal, Omer ^a   Culp, Jeff ^b   Rosenberg, Martin ^b   De Wilde, Michel ^a   Heidt, Peter ^c   Heeney, Jonathan ^c  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b GLAXOSMITHKLINE   (United Kingdom)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

chimpanzees; HIV envelope glycoprotein; vaccination

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; VACCINATION; VIRUS ENVELOPE;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMAL; BASE SEQUENCE; CLONING, MOLECULAR; COMPARATIVE STUDY; DISEASE MODELS, ANIMAL; FOLLOW-UP STUDIES; GENE PRODUCTS, ENV; GENES, ENV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEUTRALIZATION TESTS; NEUTROPHILS; PAN TROGLODYTES; PROTEIN PRECURSORS; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES; VACCINATION; VACCINES, SYNTHETIC;

EID: 0028169641     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(94)90185-6     Document Type: Article

References (32)

1. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
2. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
3. Vaccine protection of chimpanzees with HIV-1-infected peripheral blood mononuclear cells
4. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
5. Prevention of HIV infection by passive immunization with HIV immunoglobulin
6. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160
7. Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus
8. Immunoprevention of Friend virus-induced erythroleukemia by vaccination with viral envelope glycoprotein complexes
9. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom
10. Prevention of simian acquired immune deficiency syndrome with a formalin-inactivated type D retrovirus vaccine
11. Anti-cell antibodies in macaques
12. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
13. A critical determinant of lipid A endotoxic activity
14. Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells
15. Molecular cloning and characterization of the HTLV-III virus associated with AIDS
16. General method for production and selection of infectious vaccinia virus recombinants expressing foreign proteins
17. Detection of antibodies to herpes simplex virus with a continuous cell line expressing cloned glycoprotein D
18. Envelope sequences of two United States HIV-1 isolates
19. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
20. Association of antibodies blocking HIV-1 gp150-sCD4 attachment with virus-neutralizing activity in human sera
21. Challenge of chimpanzees immunizes with human immunodeficiency virus envelope glycoprotein gp120
22. Limiting dilution analysis of the cells of immune system
23. Transient high levels of viremia in patients with human immunodeficiency virus type 1 infection
24. Clonal dominance: Cause for a limited and failing immune response to HIV-1 infection and vaccination
25. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins
26. Vaccine protection against simian immunodeficiency virus infection
27. Vaccination of macaques with SIV conserved envelope peptides suppressed infection and prevented disease progression and transmission
28. SIV vaccination employing subunit proteins versus whole inactivated virus
29. Immune response to Rhesus monkeys to recombinant SIV gp130 does not protect from challenge infection
30. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus
31. Vaccination against SIV infection and disease
32. Efficacy of SIV/Delta B670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys